MF-tricyclic, with the CAS number 162011-83-8, is a chemical compound that belongs to the class of tricyclic compounds, which are characterized by their three interconnected aromatic rings. This structure often imparts unique chemical properties, including stability and the ability to engage in various chemical reactions. MF-tricyclic is primarily recognized for its applications in medicinal chemistry, particularly in the development of pharmaceuticals. Its molecular structure may influence its pharmacokinetics and pharmacodynamics, making it a subject of interest in drug design. The compound may exhibit specific biological activities, potentially interacting with various biological targets, which can lead to therapeutic effects. Additionally, tricyclic compounds often display lipophilicity, affecting their solubility and absorption in biological systems. As with many chemical substances, safety and handling precautions are essential due to potential toxicity or reactivity. Overall, MF-tricyclic exemplifies the complexity and utility of tricyclic structures in chemical and pharmaceutical research.

MF-tricyclic

162011-83-8: 2(5H)-Furanone, 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-, 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one, MF Tricyclic, 3-(3,4-Difluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone

3-(3,4-Difluorophenyl)-4-(4-Methylsulfonylphenyl)-5H-Furan-2-One (3DMPS) is a synthetic compound that has been shown to have anti-inflammatory properties. 3DMPS binds to the nuclear transcription factor NF-κB, which regulates the expression of genes that are involved in inflammation. The protein synthesis of 3DMPS is due to its ability to inhibit protein kinase C (PKC). This inhibition results in decreased levels of prostaglandin E2 (PGE2), which is necessary for cancer cell growth and invasion. 3DMPS has also been shown to be effective in chronic arthritis and atherosclerotic lesions. It has been shown to inhibit the polymerase chain reaction and protein synthesis in cancer cells lines and deficient mice with experimental models. In addition, 3DMPS has not been found to be toxic or carcinogenic when administered orally or intravenously at doses

CAS 162011-83-8: MF-tricyclic

3-(3,4-Difluorophenyl)-4-(4-Methylsulfonylphenyl)-5H-Furan-2-One

Ref: 3D-FD97543

2(5H)-Furanone, 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]-

Ref: IN-DA001SMT